Ashok Kumar P1, Ananda Babu M1, Radha Priyadharshini R3, Sudarvizhi A4
BACKGROUND
The aim of this study was to determine the safety and efficacy of posterior chamber phakic IOL in Myopic patients.
MATERIALS AND METHODS
This prospective interventional study included 50 eyes of 50 patients with myopia. Patients of age more than 18 yrs. Stable refraction, Myopia, Mild to Moderate keratoconus and absence of any ocular pathology and any history of ocular surgeries were included in this study. Prior to starting treatment certain parameters like visual acuity, AC depth, Iridocorneal Angle Aperture, Endothelial cell count, Central corneal thickness and IOP were considered. Intervention- Implantation of the phakic IOL. Main outcome Measures- Uncorrected Visual Acuity (UCVA), best spectacle corrected visual acuity (BSCVA), AS OCT AC depth-between endothelium and phakic IOL, IOP and Endothelial cell count were recorded.
RESULTS
Postoperative examinations conducted at day 1, day 3, after 1 week, 1 month and after 3 months .out of 50 patients, 4 patients had striate keratopathy, 2 patients had shallow ac during immediate post-operative period. During the postoperative follow up 10 patients had BCVA of 6/9-6/6 (20%), 14 patients had 6/9-6/12 (28%), 24 patients had 6/12-6/24(48%) and remaining 2 patients had <6/24 which was better than their preoperative uncorrected visual acuity.
CONCLUSION
Based on this prospective clinical study and on comparison with other clinical studies posterior chamber phakic IOL corrective procedures are safe and effective for treatment of myopia. It also shows that it can provide sharp and clear vision in 96% of our study population. It does not induce dry eye syndrome as in other refractive surgeries. Short term complications like endothelial damage, angle closure glaucoma, iritis, anterior capsule injury/lens changes were not encountered during our study. But still long term follow up is required to confirm long term safety of the implant.
